A phase I imaging and safety study of intravenous 131-I-TM-601 [TM-601-I-131] labeled chlorotoxin in patients with recurrent or refractory somatic and/or cerebral metastatic solid tumors

Trial Profile

A phase I imaging and safety study of intravenous 131-I-TM-601 [TM-601-I-131] labeled chlorotoxin in patients with recurrent or refractory somatic and/or cerebral metastatic solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2009

At a glance

  • Drugs TM 601 I-131 (Primary)
  • Indications Astrocytoma; Breast cancer; Colon cancer; Glioma; Non-small cell lung cancer; Pancreatic cancer; Paraganglioma; Prostate cancer; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors TransMolecular
  • Most Recent Events

    • 18 Jun 2009 Results discussed in an oral presentation at the Society for Nuclear Medicine Annual Meeting, reported by TransMolecular.
    • 01 Oct 2008 Added end date, from clinicaltrials.gov record.
    • 01 Oct 2008 Status changed from active, no longer recruiting to completed, from clincialtrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top